Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022
bởiRoshini Claire Anthony
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.
14 Sep 2022

Nicorandil improves PCI outcomes in STEMI patients
14 Sep 2022
In patients with ST‐segment–elevation myocardial infarction (STEMI), treatment with nicorandil prior to undergoing primary percutaneous coronary intervention (PCI) may result in improved myocardial perfusion grade, increased left ventricular ejection fraction, and reduced myocardial infarct size, according to data from the CHANGE* study.
14 Sep 2022







